Innovative biological machines, such as nanomotors and membrane channels, inspire the development of biomimetic devices that can provide the exquisite control of cellular processes for disease diagnostics and treatment. The phi29 is the strongest biomotor constructed to date. The motor is switchable, underscoring its highest efficiency in DNA insertion compared to all other in vitro viral packaging motors, making the motor a viable option as a mechanical component in nanotechnology applications. The long-term goal of the proposed Nanomotor Drug Delivery Center is to create biologically compatible membranes and arrays with embedded phi29 DMA-packaging motors for applications in medicine. This will be accomplished by focusing on three key areas of study: reverse engineering the phi29 motor; incorporating the active nanomotor into lipid bilayers; and developing active nanomotor arrays that enable drug delivery and diagnostics. The short-term goal of this center is to create liposomes and array structures with embedded phi29 DNA- packaging motors for both passive and active transport of DNA and drugs. The Center will develop hybrid systems that combine the best features of the biological nanomotor and synthetic delivery systems that have already achieved clinical acceptance. Initial efforts will provide engineering specifications for the structure and working mechanism of the phi29 nanomotorthat will enable us to produce engineered, hybrid, synthetic and functional nanomotors. Incorporation of active phi29 nanomotors in liposomes will be a major thrust that will enable nanoscale control for therapeutic approaches that have already gained acceptance in the clinic but still provide only blunt instruments for therapy of complex conditions such as cancer and infectious diseases. Additional team efforts will exploit our understanding of the reengineered membrane-addapted motor to create prototype nanomechanical devices for diagnostic applications, targeted delivery of therapeutics and for various nanomachines with application in medicine. These applications and the engineering principles underlying the physical action, energy transduction and transmembrane transport capabilities of the membrane adapted motors will be elucidated by our interdisciplinary team including physicists, chemists, engineers, mathematicians, physicians, and molecular biologists.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Development Center (PN2)
Project #
7PN2EY018230-02
Application #
7293563
Study Section
Special Emphasis Panel (ZEY1-VSN (13))
Program Officer
Fisher, Richard S
Project Start
2006-09-30
Project End
2011-09-29
Budget Start
2007-09-30
Budget End
2008-09-29
Support Year
2
Fiscal Year
2007
Total Cost
$1,584,416
Indirect Cost
Name
University of Cincinnati
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Haque, Farzin; Li, Jinghong; Wu, Hai-Chen et al. (2013) Solid-State and Biological Nanopore for Real-Time Sensing of Single Chemical and Sequencing of DNA. Nano Today 8:56-74
Schwartz, Chad; Guo, Peixuan (2013) Ultrastable pRNA hexameric ring gearing hexameric phi29 DNA-packaging motor by revolving without rotating and coiling. Curr Opin Biotechnol 24:581-90
Shim, Joon S; Geng, Jia; Ahn, Chong H et al. (2012) Formation of lipid bilayers inside microfluidic channel array for monitoring membrane-embedded nanopores of phi29 DNA packaging nanomotor. Biomed Microdevices 14:921-8
Guo, Peixuan; Haque, Farzin; Hallahan, Brent et al. (2012) Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther 22:226-45
Zhang, Hui; Schwartz, Chad; De Donatis, Gian Marco et al. (2012) ""Push through one-way valve"" mechanism of viral DNA packaging. Adv Virus Res 83:415-65
Laing, Brian M; Bergstrom, Donald E (2012) Evaluation of end-capped DNA modules for pRNA capture and functionalization. Bioconjug Chem 23:683-7
Li, S Kevin; Liddell, Mark R; Wen, He (2011) Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis. J Pharm Biomed Anal 55:603-7
Tarapore, Pheruza; Shu, Yi; Guo, Peixuan et al. (2011) Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. Mol Ther 19:386-94
Shukla, Girish C; Haque, Farzin; Tor, Yitzhak et al. (2011) A boost for the emerging field of RNA nanotechnology. ACS Nano 5:3405-18
Zhou, Jiehua; Shu, Yi; Guo, Peixuan et al. (2011) Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 54:284-94

Showing the most recent 10 out of 40 publications